Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|October 2, 2018
- Pharmaceutical Technology-10-02-2018
- Volume 42
- Issue 10
Pharmaceutical Technology North America, October 2018 (PDF)
Click to view Pharmaceutical Technology North America, October 2018 (PDF).
Advertisement
Articles in this issue
almost 8 years ago
Drug Delivery Innovation Funded by the Gates Foundationalmost 8 years ago
New Dose Forms Focus on the Patientalmost 8 years ago
Protecting Solid-Dose Shelf Lifealmost 8 years ago
Considering Twin-Screw Granulationalmost 8 years ago
Optimizing Containment in OSD Manufacturingalmost 8 years ago
Sartan Recalls Beg the Question: Is Compendial Impurity Testing Enough?almost 8 years ago
Developing Lipid-Based Formulationsalmost 8 years ago
Efficiency Demands Drive Advances in API Labsalmost 8 years ago
AAPS Traces the Path to ICH M10almost 8 years ago
Outsourcing Development: Small-Scale to CommercialAdvertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5